Erratum to: Lenalidomide in patients with cisplatin-refractory and multiply relapsed germ cell tumors

被引：0
|
作者：
Karin Oechsle
Carsten Bokemeyer
Friedemann Honecker
机构：
[1] University Medical Center Eppendorf,Departments of Oncology, Hematology, Bone Marrow Transplantation and Pneumology
来源：
Journal of Cancer Research and Clinical Oncology | 2010年 / 136卷 / 1期
关键词：
D O I：
10.1007/s00432-009-0697-y
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] PHASE-II TRIAL OF TOPOTECAN IN PATIENTS WITH CISPLATIN-REFRACTORY GERM-CELL TUMORS
    PUC, HS
    BAJORIN, DF
    BOSL, GJ
    AMSTERDAM, A
    MOTZER, RJ
    INVESTIGATIONAL NEW DRUGS, 1995, 13 (02) : 163 - 165
  • [22] Treatment of patients with cisplatin-refractory testicular germ-cell cancer
    Bokemeyer, C
    Kollmannsberger, C
    Harstrick, A
    Beyer, J
    Gerl, A
    Casper, J
    Metzner, B
    Hartmann, JT
    Schmoll, HJ
    Kanz, L
    INTERNATIONAL JOURNAL OF CANCER, 1999, 83 (06) : 848 - 851
  • [23] Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study
    Oechsle, K.
    Honecker, F.
    Cheng, T.
    Mayer, F.
    Czaykowski, P.
    Winquist, E.
    Wood, L.
    Fenner, M.
    Glaesener, S.
    Hartmann, J. T.
    Chi, K.
    Bokemeyer, C.
    Kollmannsberger, C.
    ANNALS OF ONCOLOGY, 2011, 22 (12) : 2654 - 2660
  • [24] Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer
    Bokemeyer, C
    Gerl, A
    Schöffski, P
    Harstrick, A
    Niederle, N
    Beyer, J
    Casper, J
    Schmoll, HJ
    Kanz, L
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (02) : 512 - 516
  • [25] Doxorubicin, Paclitaxel, and Cisplatin (ATP) for Relapsed/Refractory Germ Cell Tumors
    Xiang, Jenny J.
    Campbell, Matthew T.
    Tu, Shi-Ming
    Araujo, John
    Nieto, Yago
    Lin, John K.
    Xiao, Lianchun
    Shah, Amishi Y.
    Wang, Jianbo
    CLINICAL GENITOURINARY CANCER, 2024, 22 (06)
  • [26] Oxaliplatin-Gemcitabine combination for patients with cisplatin-refractory germ cell tumor
    De Giorgi, Ugo
    Rosti, Giovanni
    Aieta, Michele
    Testore, Franco
    Fornarini, Giuseppe
    Burattini, Luciano
    Papiani, Giorgio
    Zumaglini, Federica
    Marangolo, Maurizio
    ANNALS OF ONCOLOGY, 2005, 16 : 80 - 80
  • [27] Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer:: A study of the German Testicular Cancer Study Group
    Kollmannsberger, C
    Rick, O
    Derigs, HG
    Schleucher, N
    Schöffski, P
    Beyer, J
    Schoch, R
    Sayer, HG
    Gerl, A
    Kuczyk, M
    Spott, C
    Kanz, L
    Bokemeyer, C
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (08) : 2031 - 2037
  • [28] Treatment of patients with cisplatin-refractory germ cell tumors [Behandlung von Patienten mit cisplatinrefraktären Keimzelltumoren]
    Koychev D.
    Honecker F.
    Bokemeyer C.
    Albers P.
    Der Onkologe, 2013, 19 (7): : 564 - 567
  • [29] Preclinical and Clinical Activity of Sunitinib in Patients with Cisplatin-Refractory or Multiply Relapsed Germ Cell Tumors: A Canadian Urologic Oncology Group/German Testicular Cancer Study Group Cooperative Study Editorial Comment
    Richie, Jerome P.
    JOURNAL OF UROLOGY, 2013, 189 (02): : 533 - 534
  • [30] Cisplatin-refractory germ cell tumors. Resistance mechanisms - therapy standards - new developments
    Oing, Christoph
    Seidel, Christoph
    Alsdorf, Winfried H.
    Bokemeyer, Carsten
    ONKOLOGE, 2017, 23 (02): : 123 - 128
12345